Wegovy® is indicated for chronic weight management in adults and adolescents (12+) with obesity or overweight and at least ...

The investigational dual GLP-1 and amylin receptor agonist Amycretin demonstrated significant weight loss—up to 24% with ...

Hims & Hers will begin offering generic semaglutide drugs in Canada next year after Novo Nordisk lost its exclusive patent ...

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

Researchers conducted the REDEFINE 1 and REDEFINE 2 clinical trials to assess the effect of CagriSema on weight loss in obesity with or without type 2 diabetes.

Lately, Ozempic drugs have taken the world by storm. The drug is touted to be a magical driving force for weight loss.

Experts are warning anyone experiencing GLP-1 drug side effects to report them after launching an investigation into their safety.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss ...

The World Health Organisation (WHO) warns about the rise of fraudulent weight-loss treatments, highlighting the dangers of ...

Semaglutide is marketed under the brand names, such as Ozempic, which is primarily prescribed for those with Type 2 diabetes, and Wegovy, which is commonly prescribed for weight loss. The drug mimics ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...